1. Home
  2. FBIO
  3. FBIO News

Latest Fortress Biotech Inc. (FBIO) News on December 18, 2024

Checkpoint Therapeutics Announces FDA Approval of UNLOXCYT™ (cosibelimab-ipdl)
FBIO

GlobeNewswire

5 days ago

Checkpoint Therapeutics Announces FDA Approval of UNLOXCYT™ (cosibelimab-ipdl)

Fortress Biotech Third Quarter 2024 Earnings: Misses Expectations
FBIO

Simply Wall St.

a month ago

Fortress Biotech Third Quarter 2024 Earnings: Misses Expectations

FBIO

Associated Press Finance

a month ago

Fortress Biotech: Q3 Earnings Snapshot

Fortress Biotech Reports Third Quarter 2024 Financial Results and Recent Corporate Highlights
FBIO

GlobeNewswire

a month ago

Fortress Biotech Reports Third Quarter 2024 Financial Results and Recent Corporate Highlights

Avenue Therapeutics Reports Third Quarter 2024 Financial Results and Recent Corporate Highlights
FBIO

GlobeNewswire

a month ago

Avenue Therapeutics Reports Third Quarter 2024 Financial Results and Recent Corporate Highlights

Checkpoint Therapeutics Reports Third Quarter 2024 Financial Results and Recent Corporate Updates
FBIO

GlobeNewswire

a month ago

Checkpoint Therapeutics Reports Third Quarter 2024 Financial Results and Recent Corporate Updates

Journey Medical Corporation Reports Third Quarter 2024 Financial Results and Recent Corporate Highlights
FBIO

GlobeNewswire

a month ago

Journey Medical Corporation Reports Third Quarter 2024 Financial Results and Recent Corporate Highlights

Mustang Bio Receives Positive Listing Determination from Nasdaq
FBIO

GlobeNewswire

a month ago

Mustang Bio Receives Positive Listing Determination from Nasdaq

Mustang Bio Granted Orphan Drug Designation by U.S. FDA for MB-108 (HSV-1 oncolytic virus) to Treat Malignant Glioma
FBIO

GlobeNewswire

a month ago

Mustang Bio Granted Orphan Drug Designation by U.S. FDA for MB-108 (HSV-1 oncolytic virus) to Treat Malignant Glioma

Journey Medical Corporation Announces U.S. FDA Approval of Emrosi™ (Minocycline Hydrochloride Extended Release Capsules, 40 mg) for the Treatment of Rosacea
FBIO

GlobeNewswire

a month ago

Journey Medical Corporation Announces U.S. FDA Approval of Emrosi™ (Minocycline Hydrochloride Extended Release Capsules, 40 mg) for the Treatment of Rosacea

Fortress Biotech Insiders Placed Bullish Bets Worth US$4.49m
FBIO

Simply Wall St.

2 months ago

Fortress Biotech Insiders Placed Bullish Bets Worth US$4.49m

Highbridge Capital Management's Strategic Acquisition of Fortress Biotech Shares
FBIO

GuruFocus.com

2 months ago

Highbridge Capital Management's Strategic Acquisition of Fortress Biotech Shares

Journey Medical Corporation Announces DFD-29 Data Presented at 44th Fall Clinical Dermatology Conference
FBIO

GlobeNewswire

2 months ago

Journey Medical Corporation Announces DFD-29 Data Presented at 44th Fall Clinical Dermatology Conference

Mustang Bio Announces Exercise of Warrants for $4 Million Gross Proceeds
FBIO

GlobeNewswire

2 months ago

Mustang Bio Announces Exercise of Warrants for $4 Million Gross Proceeds

Avenue Therapeutics to Participate in Maxim Group’s 2024 Healthcare Virtual Summit
FBIO

GlobeNewswire

2 months ago

Avenue Therapeutics to Participate in Maxim Group’s 2024 Healthcare Virtual Summit

Journey Medical Corporation to Participate in the 3rd Annual ROTH Healthcare Opportunities Conference
FBIO

GlobeNewswire

3 months ago

Journey Medical Corporation to Participate in the 3rd Annual ROTH Healthcare Opportunities Conference

FBIO

MT Newswires

3 months ago

Fortress Biotech Files Registration Statement on Behalf of Selling Shareholders

Fortress Biotech to Participate in October 2024 Investor Conferences
FBIO

GlobeNewswire

3 months ago

Fortress Biotech to Participate in October 2024 Investor Conferences

FBIO

Argus Research

3 months ago

Daily – Vickers Top Buyers & Sellers for 09/26/2024

FBIO

MT Newswires

3 months ago

Fortress Biotech Prices Registered Direct Offering, Private Placements; Shares Fall

Fortress Biotech Announces Pricing of $8 Million Registered Direct Offering and Concurrent Private Placements
FBIO

GlobeNewswire

3 months ago

Fortress Biotech Announces Pricing of $8 Million Registered Direct Offering and Concurrent Private Placements

Checkpoint Therapeutics Announces Cosibelimab Longer-Term Results in Advanced Cutaneous Squamous Cell Carcinoma Presented at ESMO Congress 2024
FBIO

GlobeNewswire

3 months ago

Checkpoint Therapeutics Announces Cosibelimab Longer-Term Results in Advanced Cutaneous Squamous Cell Carcinoma Presented at ESMO Congress 2024

Journey Medical Corporation to Participate in the Lake Street Capital Markets 8th Annual Best Ideas Growth (BIG) Conference
FBIO

GlobeNewswire

3 months ago

Journey Medical Corporation to Participate in the Lake Street Capital Markets 8th Annual Best Ideas Growth (BIG) Conference

Fortress Biotech to Present at the H.C. Wainwright 26th Annual Global Investment Conference
FBIO

GlobeNewswire

3 months ago

Fortress Biotech to Present at the H.C. Wainwright 26th Annual Global Investment Conference

Journey Medical Corporation to Present at the H.C. Wainwright 26th Annual Global Investment Conference
FBIO

GlobeNewswire

3 months ago

Journey Medical Corporation to Present at the H.C. Wainwright 26th Annual Global Investment Conference

Checkpoint Therapeutics to Present at H.C. Wainwright 26th Annual Global Investment Conference
FBIO

GlobeNewswire

3 months ago

Checkpoint Therapeutics to Present at H.C. Wainwright 26th Annual Global Investment Conference

Avenue Therapeutics to Participate in Upcoming Investor Conferences
FBIO

GlobeNewswire

3 months ago

Avenue Therapeutics to Participate in Upcoming Investor Conferences

Fortress Biotech (FBIO) Shows Fast-paced Momentum But Is Still a Bargain Stock
FBIO

Zacks

4 months ago

Fortress Biotech (FBIO) Shows Fast-paced Momentum But Is Still a Bargain Stock

Fortress Biotech (FBIO) Reports Q2 Loss, Lags Revenue Estimates
FBIO

Zacks

4 months ago

Fortress Biotech (FBIO) Reports Q2 Loss, Lags Revenue Estimates

FBIO

Associated Press Finance

4 months ago

Fortress Biotech: Q2 Earnings Snapshot

Fortress Biotech Reports Second Quarter 2024 Financial Results and Recent Corporate Highlights
FBIO

GlobeNewswire

4 months ago

Fortress Biotech Reports Second Quarter 2024 Financial Results and Recent Corporate Highlights

Journey Medical Corporation Reports Second Quarter 2024 Financial Results and Recent Corporate Highlights
FBIO

GlobeNewswire

4 months ago

Journey Medical Corporation Reports Second Quarter 2024 Financial Results and Recent Corporate Highlights

Checkpoint Therapeutics Reports Second Quarter 2024 Financial Results and Recent Corporate Updates
FBIO

GlobeNewswire

4 months ago

Checkpoint Therapeutics Reports Second Quarter 2024 Financial Results and Recent Corporate Updates

Avenue Therapeutics Reports Second Quarter 2024 Financial Results and Recent Corporate Highlights
FBIO

GlobeNewswire

4 months ago

Avenue Therapeutics Reports Second Quarter 2024 Financial Results and Recent Corporate Highlights

Phathom Pharmaceuticals, Inc. (PHAT) Reports Q2 Loss, Tops Revenue Estimates
FBIO

Zacks

4 months ago

Phathom Pharmaceuticals, Inc. (PHAT) Reports Q2 Loss, Tops Revenue Estimates

Journey Medical Corporation to Announce Second Quarter 2024 Financial Results on August 12, 2024
FBIO

GlobeNewswire

4 months ago

Journey Medical Corporation to Announce Second Quarter 2024 Financial Results on August 12, 2024

Fortress Biotech Reduces Total Debt and Enters into New $35 Million Term Loan with Oaktree with Maturity in 2027
FBIO

GlobeNewswire

5 months ago

Fortress Biotech Reduces Total Debt and Enters into New $35 Million Term Loan with Oaktree with Maturity in 2027

Checkpoint Therapeutics Announces FDA Acceptance of BLA Resubmission of Cosibelimab for the Treatment of Advanced Cutaneous Squamous Cell Carcinoma
FBIO

GlobeNewswire

5 months ago

Checkpoint Therapeutics Announces FDA Acceptance of BLA Resubmission of Cosibelimab for the Treatment of Advanced Cutaneous Squamous Cell Carcinoma

FBIO

Argus Research

5 months ago

Daily – Vickers Top Buyers & Sellers for 07/16/2024

Here Is Why Bargain Hunters Would Love Fast-paced Mover Fortress Biotech (FBIO)
FBIO

Zacks

5 months ago

Here Is Why Bargain Hunters Would Love Fast-paced Mover Fortress Biotech (FBIO)

GC Cell and Checkpoint Therapeutics Advance Collaborative Cancer Research
FBIO

GlobeNewswire

5 months ago

GC Cell and Checkpoint Therapeutics Advance Collaborative Cancer Research

Journey Medical Corporation Appoints Michael C. Pearce to Board of Directors
FBIO

GlobeNewswire

5 months ago

Journey Medical Corporation Appoints Michael C. Pearce to Board of Directors

Fortress Biotech Announces Pause in Payment of Dividends on 9.375% Series A Cumulative Redeemable Perpetual Preferred Stock
FBIO

GlobeNewswire

5 months ago

Fortress Biotech Announces Pause in Payment of Dividends on 9.375% Series A Cumulative Redeemable Perpetual Preferred Stock

Checkpoint Therapeutics Announces $12 Million Registered Direct Offering Priced At-the-Market Under Nasdaq Rules
FBIO

GlobeNewswire

6 months ago

Checkpoint Therapeutics Announces $12 Million Registered Direct Offering Priced At-the-Market Under Nasdaq Rules

Checkpoint Therapeutics Announces Biologics License Application Resubmission for Cosibelimab
FBIO

GlobeNewswire

6 months ago

Checkpoint Therapeutics Announces Biologics License Application Resubmission for Cosibelimab

Checkpoint Therapeutics Announces Alignment with FDA Enabling Upcoming Cosibelimab BLA Resubmission
FBIO

GlobeNewswire

6 months ago

Checkpoint Therapeutics Announces Alignment with FDA Enabling Upcoming Cosibelimab BLA Resubmission

Mustang Bio Announces Closing of $2.5 Million Registered Direct Offering Priced At-the-Market Under Nasdaq Rules
FBIO

GlobeNewswire

6 months ago

Mustang Bio Announces Closing of $2.5 Million Registered Direct Offering Priced At-the-Market Under Nasdaq Rules

Avenue Therapeutics to Present at the H.C. Wainwright 5th Annual Neuro Perspectives Virtual Conference
FBIO

GlobeNewswire

6 months ago

Avenue Therapeutics to Present at the H.C. Wainwright 5th Annual Neuro Perspectives Virtual Conference

Mustang Bio Announces $2.5 Million Registered Direct Offering Priced At-the-Market Under Nasdaq Rules
FBIO

GlobeNewswire

6 months ago

Mustang Bio Announces $2.5 Million Registered Direct Offering Priced At-the-Market Under Nasdaq Rules

Mustang Bio Announces Favorable Efficacy and Safety Data from Complete Waldenstrom Macroglobulinemia Cohort of Phase 1/2 Clinical Trial of MB-106, CD20-Targeted Autologous CAR-T Therapy
FBIO

GlobeNewswire

6 months ago

Mustang Bio Announces Favorable Efficacy and Safety Data from Complete Waldenstrom Macroglobulinemia Cohort of Phase 1/2 Clinical Trial of MB-106, CD20-Targeted Autologous CAR-T Therapy

Engelhart Commodities Trading Partners Agrees to Acquire Trailstone, Strengthening Commitment to the Energy Transition
FBIO

Business Wire

6 months ago

Engelhart Commodities Trading Partners Agrees to Acquire Trailstone, Strengthening Commitment to the Energy Transition

Delfi Meedia, a subsidiary of AS Ekspress Grupp to acquire business operations of Eesti Koolitus- ja Konverentsikeskus
FBIO

GlobeNewswire

6 months ago

Delfi Meedia, a subsidiary of AS Ekspress Grupp to acquire business operations of Eesti Koolitus- ja Konverentsikeskus

Share buy-back programme - week 23
FBIO

GlobeNewswire

6 months ago

Share buy-back programme - week 23

Do Scientex Berhad's (KLSE:SCIENTX) Earnings Warrant Your Attention?
FBIO

Simply Wall St.

6 months ago

Do Scientex Berhad's (KLSE:SCIENTX) Earnings Warrant Your Attention?

Japan's service sector mood hits nearly 2-year low in May
FBIO

Reuters

6 months ago

Japan's service sector mood hits nearly 2-year low in May

N. Korea sends more balloons as Kim's sister warns of 'new counteraction'
FBIO

AFP

6 months ago

N. Korea sends more balloons as Kim's sister warns of 'new counteraction'

Enduring role of 'treasuring the past' hailed
FBIO

PR Newswire

6 months ago

Enduring role of 'treasuring the past' hailed

Velcan Holdings: buyback offer of 500 000 shares at Eur 14.5 per share
FBIO

GlobeNewswire

6 months ago

Velcan Holdings: buyback offer of 500 000 shares at Eur 14.5 per share

Avenue Therapeutics Announces Last Patient Last Visit in Phase 1b/2a Clinical Trial of AJ201 for the Treatment of Spinal and Bulbar Muscular Atrophy (Kennedy's Disease)
FBIO

GlobeNewswire

7 months ago

Avenue Therapeutics Announces Last Patient Last Visit in Phase 1b/2a Clinical Trial of AJ201 for the Treatment of Spinal and Bulbar Muscular Atrophy (Kennedy's Disease)

Fortress Biotech to Participate in the Alliance Global Partners’ (A.G.P.) Virtual Healthcare Company Showcase
FBIO

GlobeNewswire

7 months ago

Fortress Biotech to Participate in the Alliance Global Partners’ (A.G.P.) Virtual Healthcare Company Showcase

FBIO

Associated Press Finance

7 months ago

Fortress Biotech: Q1 Earnings Snapshot

Fortress Biotech Reports First Quarter 2024 Financial Results and Recent Corporate Highlights
FBIO

GlobeNewswire

7 months ago

Fortress Biotech Reports First Quarter 2024 Financial Results and Recent Corporate Highlights

Journey Medical Corporation to Participate in the Alliance Global Partners’ (A.G.P.) Virtual Healthcare Company Showcase
FBIO

GlobeNewswire

7 months ago

Journey Medical Corporation to Participate in the Alliance Global Partners’ (A.G.P.) Virtual Healthcare Company Showcase

AquaBounty Technologies, Inc. (AQB) Reports Q1 Loss, Misses Revenue Estimates
FBIO

Zacks

7 months ago

AquaBounty Technologies, Inc. (AQB) Reports Q1 Loss, Misses Revenue Estimates

Avenue Therapeutics Reports First Quarter 2024 Financial Results and Recent Corporate Highlights
FBIO

GlobeNewswire

7 months ago

Avenue Therapeutics Reports First Quarter 2024 Financial Results and Recent Corporate Highlights

FBIO

MT Newswires

7 months ago

Fortress Biotech Says First Patient Dosed in Phase 2 Study of Triplex

Fortress Biotech Announces First Patient Dosed in Multi-Center Phase 2 Study of Triplex for Control of CMV in Patients Undergoing Liver Transplantation
FBIO

GlobeNewswire

7 months ago

Fortress Biotech Announces First Patient Dosed in Multi-Center Phase 2 Study of Triplex for Control of CMV in Patients Undergoing Liver Transplantation

Journey Medical Corporation Reports First Quarter 2024 Financial Results and Recent Corporate Highlights
FBIO

GlobeNewswire

7 months ago

Journey Medical Corporation Reports First Quarter 2024 Financial Results and Recent Corporate Highlights

Checkpoint Therapeutics to Participate in the H.C. Wainwright 2nd Annual BioConnect Investor Conference
FBIO

GlobeNewswire

7 months ago

Checkpoint Therapeutics to Participate in the H.C. Wainwright 2nd Annual BioConnect Investor Conference

Checkpoint Therapeutics Reports First Quarter 2024 Financial Results and Recent Corporate Updates
FBIO

GlobeNewswire

7 months ago

Checkpoint Therapeutics Reports First Quarter 2024 Financial Results and Recent Corporate Updates

Journey Medical Corporation to Announce First Quarter 2024 Financial Results on May 13, 2024
FBIO

GlobeNewswire

7 months ago

Journey Medical Corporation to Announce First Quarter 2024 Financial Results on May 13, 2024

Mustang Bio Announces Closing of $4 Million Public Offering
FBIO

GlobeNewswire

8 months ago

Mustang Bio Announces Closing of $4 Million Public Offering

Journey Medical Corporation Appoints Joseph Benesch as Chief Financial Officer
FBIO

GlobeNewswire

8 months ago

Journey Medical Corporation Appoints Joseph Benesch as Chief Financial Officer

Mustang Bio Announces Pricing of $4 Million Public Offering
FBIO

GlobeNewswire

8 months ago

Mustang Bio Announces Pricing of $4 Million Public Offering

Avenue Therapeutics Announces Exercise of Warrants for $4.4 Million in Gross Proceeds
FBIO

GlobeNewswire

8 months ago

Avenue Therapeutics Announces Exercise of Warrants for $4.4 Million in Gross Proceeds

Journey Medical Corporation to Present at the Planet MicroCap Showcase: Vegas 2024
FBIO

GlobeNewswire

8 months ago

Journey Medical Corporation to Present at the Planet MicroCap Showcase: Vegas 2024

Avenue Therapeutics Announces Reverse Stock Split
FBIO

GlobeNewswire

8 months ago

Avenue Therapeutics Announces Reverse Stock Split

Fortress Biotech Reports 2023 Financial Results and Recent Corporate Highlights
FBIO

GlobeNewswire

9 months ago

Fortress Biotech Reports 2023 Financial Results and Recent Corporate Highlights

Mustang Bio Announces Vision for CAR T-Cell Therapy Platform Expansion into Autoimmune Diseases
FBIO

GlobeNewswire

9 months ago

Mustang Bio Announces Vision for CAR T-Cell Therapy Platform Expansion into Autoimmune Diseases

Avenue Therapeutics to Host Virtual Key Opinion Leader (KOL) Event on April 4, 2024
FBIO

GlobeNewswire

9 months ago

Avenue Therapeutics to Host Virtual Key Opinion Leader (KOL) Event on April 4, 2024

Checkpoint Therapeutics Reports Full-Year 2023 Financial Results and Recent Corporate Highlights
FBIO

GlobeNewswire

9 months ago

Checkpoint Therapeutics Reports Full-Year 2023 Financial Results and Recent Corporate Highlights

Journey Medical Corporation Reports Full-Year 2023 Financial Results and Recent Corporate Highlights
FBIO

GlobeNewswire

9 months ago

Journey Medical Corporation Reports Full-Year 2023 Financial Results and Recent Corporate Highlights

Avenue Therapeutics Reports Full Year 2023 Financial Results and Recent Corporate Highlights
FBIO

GlobeNewswire

9 months ago

Avenue Therapeutics Reports Full Year 2023 Financial Results and Recent Corporate Highlights

Journey Medical Corporation Announces U.S. FDA Acceptance of New Drug Application for DFD-29 for the Treatment of Rosacea
FBIO

GlobeNewswire

9 months ago

Journey Medical Corporation Announces U.S. FDA Acceptance of New Drug Application for DFD-29 for the Treatment of Rosacea

Checkpoint Therapeutics Announces Appointment of Accomplished Life Sciences Executive Amit Sharma, M.D. to Board of Directors
FBIO

GlobeNewswire

9 months ago

Checkpoint Therapeutics Announces Appointment of Accomplished Life Sciences Executive Amit Sharma, M.D. to Board of Directors

Journey Medical Corporation to Announce Year End 2023 Financial Results on March 21, 2024
FBIO

GlobeNewswire

9 months ago

Journey Medical Corporation to Announce Year End 2023 Financial Results on March 21, 2024

Avenue Therapeutics Receives Positive Listing Determination from Nasdaq
FBIO

GlobeNewswire

9 months ago

Avenue Therapeutics Receives Positive Listing Determination from Nasdaq

Journey Medical Corporation to Participate in the 36th Annual ROTH Conference
FBIO

GlobeNewswire

9 months ago

Journey Medical Corporation to Participate in the 36th Annual ROTH Conference

Fortress Biotech to Participate in 36th Annual ROTH Conference
FBIO

GlobeNewswire

9 months ago

Fortress Biotech to Participate in 36th Annual ROTH Conference

Journey Medical Corporation Announces Presentation of Data from Phase 1 Clinical Trial Assessing the Impact of DFD-29 (Minocycline Hydrochloride Modified Release Capsules, 40 mg) on Microbial Flora of Healthy Adults at 2024 AAD Annual Meeting
FBIO

GlobeNewswire

9 months ago

Journey Medical Corporation Announces Presentation of Data from Phase 1 Clinical Trial Assessing the Impact of DFD-29 (Minocycline Hydrochloride Modified Release Capsules, 40 mg) on Microbial Flora of Healthy Adults at 2024 AAD Annual Meeting

Avenue Therapeutics to Present BAER-101 Preclinical Data at American Society for Experimental Neurotherapeutics (ASENT) 2024 Annual Meeting
FBIO

GlobeNewswire

9 months ago

Avenue Therapeutics to Present BAER-101 Preclinical Data at American Society for Experimental Neurotherapeutics (ASENT) 2024 Annual Meeting

Mustang Bio Announces Publication in Nature Medicine of Data from Phase 1 Trial Evaluating MB-101 IL13Rα2-targeted CAR T-Cells in High-Grade Glioma
FBIO

GlobeNewswire

9 months ago

Mustang Bio Announces Publication in Nature Medicine of Data from Phase 1 Trial Evaluating MB-101 IL13Rα2-targeted CAR T-Cells in High-Grade Glioma

Fortress Biotech and Cyprium Therapeutics Announce $4.1 Million Grant from NINDS to Further Development of AAV-ATP7A Gene Therapy for Menkes Disease
FBIO

GlobeNewswire

9 months ago

Fortress Biotech and Cyprium Therapeutics Announce $4.1 Million Grant from NINDS to Further Development of AAV-ATP7A Gene Therapy for Menkes Disease

Avenue Therapeutics Announces Publication in Drug Development Research Highlighting First-In-Class Preclinical Data of BAER-101 in a Translational Model of Absence Epilepsy
FBIO

GlobeNewswire

10 months ago

Avenue Therapeutics Announces Publication in Drug Development Research Highlighting First-In-Class Preclinical Data of BAER-101 in a Translational Model of Absence Epilepsy

Insider Stock Buying Reaches US$3.06m On Fortress Biotech
FBIO

Simply Wall St.

10 months ago

Insider Stock Buying Reaches US$3.06m On Fortress Biotech

Lindsay Rosenwald’s Fortress Bio (NASDAQ: FBIO) Spotlight on 2024 Milestones from Subsidiaries
FBIO

News Direct

a year ago

Lindsay Rosenwald’s Fortress Bio (NASDAQ: FBIO) Spotlight on 2024 Milestones from Subsidiaries

Invesco Closed-End Funds Pay Dividends
FBIO

PR Newswire

a year ago

Invesco Closed-End Funds Pay Dividends

Alarum: NetNut Enhances Data Collection Offering - Launching its Second Innovative Product
FBIO

GlobeNewswire

a year ago

Alarum: NetNut Enhances Data Collection Offering - Launching its Second Innovative Product

Checkpoint Therapeutics Announces $14 Million Registered Direct Offering Priced At-the-Market
FBIO

GlobeNewswire

a year ago

Checkpoint Therapeutics Announces $14 Million Registered Direct Offering Priced At-the-Market

Fluent Secures Top Spot as the #1 Digital Agency in Ad Age's 2024 Best Places to Work List
FBIO

GlobeNewswire

a year ago

Fluent Secures Top Spot as the #1 Digital Agency in Ad Age's 2024 Best Places to Work List

Share on Social Networks: